🌏 Import-Export Trade Data
China is the world's largest exporter of peptide APIs, supplying over 38% of global volume. This chapter compiles China's peptide API import-export data, tracking trade flows, export value trends, and policy impacts, with in-depth analysis of major exporters, destination structures, and trade policy risks.
1. China Peptide API Export Value and Annual Data (2018–2024)
| Year |
Total Export Value ($M) |
YoY Growth |
Total Export Volume (kg) |
Average Unit Price ($/kg) |
Share of Global Supply |
| 2018 |
620 |
— |
320 |
1,938 |
22% |
| 2019 |
680 |
+9.7% |
340 |
2,000 |
24% |
| 2020 |
880 |
+29.4% |
360 |
2,445 |
28% |
| 2021 |
1,050 |
+19.3% |
392 |
2,678 |
30% |
| 2022 |
1,320 |
+25.7% |
425 |
3,106 |
33% |
| 2023 |
1,580 |
+19.7% |
410 |
3,854 |
36% |
| 2024 |
1,820 |
+15.2% |
433 |
4,203 |
38% |
Key Findings
Between 2018 and 2024, China's peptide API export value grew at a CAGR of 19.7%, from $620M to $1.82B. Notable observations:
- Significant unit price appreciation: From $1,938/kg in 2018 to $4,203/kg in 2024 (+117%), reflecting a product mix shift toward higher-value long-chain peptides
- Volume growth slowing: Export volume growth moderated in 2023–2024 (with 2023 even seeing a 3.5% year-on-year decline), indicating capacity constraints limiting volume expansion
- Value growth driven by unit price: Post-2020, value growth has come primarily from unit price increases rather than volume expansion
2. Export Destination Distribution (2024)
Top 10 Export Destinations (2024)
| Rank |
Destination / Region |
Export Value ($M) |
Share |
YoY Growth |
Key Product Demand |
| 1 |
United States |
620 |
34.1% |
+22% |
GLP-1 APIs, cosmetic peptide intermediates |
| 2 |
European Union |
420 |
23.1% |
+12% |
Semaglutide intermediates, Liraglutide API |
| 3 |
India |
290 |
15.9% |
+28% |
GLP-1 APIs, non-GLP-1 generic APIs |
| 4 |
Japan |
180 |
9.9% |
+8% |
Cosmetic peptides, functional food peptides |
| 5 |
South Korea |
95 |
5.2% |
+18% |
Cosmetic peptides, GLP-1 clinical APIs |
| 6 |
Switzerland |
55 |
3.0% |
+5% |
High-end custom peptides |
| 7 |
Brazil |
32 |
1.8% |
+25% |
Liraglutide generic API |
| 8 |
Australia |
25 |
1.4% |
+15% |
Research-grade peptides |
| 9 |
Russia |
20 |
1.1% |
+30% |
Thymalfasin and other immune peptides |
| 10 |
Israel |
18 |
1.0% |
+10% |
Innovative drug clinical-stage peptides |
|
Top 10 Total |
1,755 |
96.4% |
— |
— |
|
Other |
65 |
3.6% |
— |
— |
Destination Growth Trends (2020–2024)
| Destination |
2020 ($M) |
2021 ($M) |
2022 ($M) |
2023 ($M) |
2024 ($M) |
CAGR |
| United States |
260 |
320 |
440 |
510 |
620 |
24.3% |
| European Union |
230 |
260 |
340 |
380 |
420 |
16.3% |
| India |
100 |
130 |
180 |
230 |
290 |
30.5% |
| Japan |
110 |
130 |
150 |
165 |
180 |
13.1% |
| South Korea |
40 |
50 |
65 |
80 |
95 |
24.1% |
| Switzerland |
25 |
30 |
38 |
48 |
55 |
21.7% |
| Brazil |
8 |
12 |
18 |
25 |
32 |
41.4% |
| Australia |
10 |
12 |
16 |
20 |
25 |
25.7% |
3. Major Exporters and Export Scale (2024 Estimated)
| Rank |
Company |
Peptide API Export Value ($M) |
Key Export Products |
Main Destinations |
Export Share |
| 1 |
WuXi AppTec (WuXi Tides) |
~380 |
GLP-1 APIs, custom peptides |
US, EU |
21% |
| 2 |
Sinopeptide |
~280 |
Semaglutide, Tirzepatide APIs |
US, India |
15% |
| 3 |
Shenggene |
~120 |
Cosmetic peptides, GLP-1 generic APIs |
Japan, South Korea, US |
7% |
| 4 |
Hybio |
~110 |
Liraglutide, Terlipressin APIs |
EU, US |
6% |
| 5 |
GenScript |
~95 |
Research-grade peptides, custom synthesis |
US, EU |
5% |
| 6 |
Aurisco |
~80 |
GLP-1 intermediates, specialty APIs |
India, EU |
4% |
| 7 |
Shuangcheng Pharma |
~45 |
Thymalfasin, Somatostatin APIs |
Russia, India |
2.5% |
| 8 |
GL Biochem |
~40 |
Short-chain cosmetic peptides, intermediates |
Japan, South Korea |
2.2% |
| 9 |
AmbioPharm |
~35 |
Medium-chain therapeutic peptides |
US |
1.9% |
| 10 |
CPC Scientific |
~30 |
Short-chain custom peptides |
US, EU |
1.6% |
|
Top 10 Total |
~1,215 |
— |
— |
66.8% |
|
Other Companies |
~605 |
Multiple product types |
Multiple regions |
33.2% |
Industry Concentration
China's peptide API export market is moderately concentrated, with the top 10 companies accounting for 66.8% of total export value. WuXi AppTec and Sinopeptide alone contribute 36% of exports, reflecting the competitive advantages and scale effects of top-tier CDMOs. SMEs are primarily active in niche markets such as cosmetic peptides and short-chain research-grade peptides.
4. China Peptide API Import Data
Annual Import Data (2018–2024)
| Year |
Total Import Value ($M) |
YoY Growth |
Key Source Countries |
Key Products |
| 2018 |
180 |
— |
Switzerland, US |
Patent-protected innovative drug APIs |
| 2019 |
195 |
+8.3% |
Switzerland, US, Belgium |
Innovative peptide APIs |
| 2020 |
210 |
+7.7% |
Switzerland, US, Belgium |
Patent-protected innovative drug APIs |
| 2021 |
230 |
+9.5% |
Switzerland, US, Denmark |
Semaglutide originator API |
| 2022 |
260 |
+13.0% |
Switzerland, Belgium, Denmark |
Innovative peptide drug imported APIs |
| 2023 |
240 |
−7.7% |
Switzerland, US |
Import substitution beginning |
| 2024 |
220 |
−8.3% |
Switzerland, US |
Import substitution accelerating |
Import Source Country Breakdown (2024)
| Source Country |
Import Value ($M) |
Share |
Key Products |
| Switzerland |
98 |
44.5% |
Bachem high-end long-chain peptides, innovative drug APIs |
| United States |
62 |
28.2% |
Patent-protected innovative peptide APIs |
| Denmark |
28 |
12.7% |
Novo Nordisk originator GLP-1 APIs |
| Belgium |
18 |
8.2% |
Innovative drug clinical-stage APIs |
| Other |
14 |
6.4% |
Specialty peptides, diagnostic-grade peptides |
Import Substitution Trend
China's peptide API imports peaked at $260M in 2022 and have since declined, reaching $220M in 2024 (down 15.4% from peak). The accelerating import substitution is driven by:
- Improved domestic GMP capacity meeting local demand
- WuXi AppTec and Sinopeptide securing API supply contracts with multinational pharma companies
- Domestic generic manufacturers building captive API capacity
- CDE acceptance of domestic API substitution for imported APIs through joint review
5. Trade Policy and Geopolitical Impacts
| Policy / Event |
Timing |
Impact Assessment |
Response Strategy |
| US BIOSECURE Act Debate |
2024–2025 |
Medium- to long-term may restrict some China CDMOs from US government-funded projects |
Top CDMOs accelerating overseas plant construction (Singapore, Europe) |
| China Drug Administration Law Revision (API Joint Review) |
2020 |
Raised API export compliance threshold; benefits GMP-compliant companies |
Compliant firms accelerating FDA/EMA/PMDA certification acquisition |
| EU API Import New Rules (GMP Equivalence Declaration) |
2023 |
Third-country API exports to EU require equivalence declaration |
Top firms passing EU GMP site inspections early |
| India Peptide API Tariff Adjustment |
2024 |
10% tariff on imported GLP-1 APIs to encourage localization |
Chinese companies establishing joint ventures in India |
| US Section 301 Tariffs (on China) |
2025 (proposed) |
Proposed additional 7.5–25% tariffs on peptide APIs |
Supply chain restructuring; third-country transshipment planning |
| EU FMD (Falsified Medicines Directive) |
2025 (full implementation) |
Requires unique identifier on each batch of API |
Investment in traceability systems; increased compliance costs |
| India PLI Peptide Scheme |
2024 launch |
Indian government subsidies for domestic peptide API capacity |
China's export growth rate to India may moderate |
| RCEP Rules of Origin |
2022 effective |
Tariff preferences for peptide APIs among China, Japan, South Korea |
Enhanced export competitiveness to Japan and South Korea |
Trade Policy Quantitative Impact Assessment
| Policy Scenario |
Impact on China Peptide API Exports |
Probability |
Time Window |
| Baseline (Current Policies Continue) |
2025E exports $2.1–2.3B |
55% |
2025–2027 |
| Escalated Trade Friction (US Tariffs 25%) |
Exports to US decline 15–30% |
25% |
2025–2026 |
| India Localization Accelerates (PLI Takes Effect) |
Export growth to India drops from 28% to 5–10% |
15% |
2026–2028 |
| Worst Case (Dual Shock) |
Total exports decline 10–20% |
5% |
2026–2027 |
6. Trade Outlook (2025–2027)
| Year |
Estimated Export Value ($M) |
Growth Rate |
Core Rationale |
| 2025E |
2,100–2,300 |
+15–20% |
GLP-1 API export volume continues growing; higher-value products increase share |
| 2026E |
2,500–2,800 |
+12–18% |
Semaglutide China patent expires; generic API exports surge |
| 2027E |
2,800–3,200 |
+10–15% |
India/Europe domestic capacity gradually releases; growth moderates but China stays ahead |
Product-Level Export Outlook
| Product Category |
2024 Export Value ($M) |
2027E Export Value ($M) |
CAGR |
Core Driver |
| GLP-1 APIs |
680 |
1,450 |
28.7% |
Post-patent-expiry generic API export surge |
| Cosmetic Peptide Intermediates |
250 |
310 |
7.4% |
Steady cosmetics market growth |
| Non-GLP-1 Therapeutic APIs |
320 |
380 |
5.9% |
Stable demand for classic products |
| Research-Grade Peptides |
180 |
200 |
3.6% |
Intensified market competition; unit price decline |
| Health Food Peptides |
130 |
155 |
6.0% |
Functional food demand in Japan/Southeast Asia |
Data Sources: China General Administration of Customs HS codes 2937 (peptide hormones) and 2934 (other peptides) import-export statistics. Export values based on FOB (Free on Board) reporting. Company-level export data are reasonable estimates based on public information and industry association data. For custom import-export data analysis by HS code, supplier, or compound — visit the dedicated trade data service for exclusive trade intelligence, including global peptide API trade flow maps and competitor export tracking.